Edition:
India

Syros Pharmaceuticals Inc (SYRS.OQ)

SYRS.OQ on NASDAQ Stock Exchange Global Select Market

12.09USD
1:30am IST
Change (% chg)

$0.07 (+0.58%)
Prev Close
$12.02
Open
$12.06
Day's High
$12.38
Day's Low
$12.06
Volume
21,141
Avg. Vol
83,384
52-wk High
$24.35
52-wk Low
$6.31

Chart for

About

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments... (more)

Overall

Beta: --
Market Cap(Mil.): $420.43
Shares Outstanding(Mil.): 26.26
Dividend: --
Yield (%): --

Financials

  SYRS.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -1.86 -- --
ROI: -68.14 14.84 14.38
ROE: -442.37 16.34 16.07

BRIEF-Syros Pharmaceuticals Reports Q4 Loss Per Share $0.58

* SYROS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT ACCOMPLISHMENTS AND ANTICIPATED MILESTONES

12 Mar 2018

BRIEF-Syros Pharmaceuticals Enters Amendment To Stock Purchase Agreement With Incyte

* SYROS PHARMACEUTICALS -‍ ON JAN 31, ENTERED AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT WITH INCYTE TO FACILITATE PRIVATE PLACEMENT - SEC FILING​

31 Jan 2018

BRIEF-Syros Prices Public Offering Of 4.19 Mln Common Shares At $9.55/Share

* SYROS ANNOUNCES PRICING OF $40 MILLION PUBLIC OFFERING OF COMMON STOCK

31 Jan 2018

BRIEF-Syros Announces Proposed Offering Of Common Stock

* SYROS PHARMACEUTICALS INC - ‍OFFERING TO SELL $40.0 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING​ Source text for Eikon: Further company coverage:

31 Jan 2018

BRIEF-Incyte Corp - Co, Syros Pharmaceuticals Have Entered Into Target Discovery, Research Collaboration And Option Agreement

* INCYTE CORP - CO, SYROS PHARMACEUTICALS HAVE ENTERED INTO A TARGET DISCOVERY, RESEARCH COLLABORATION AND OPTION AGREEMENT

08 Jan 2018

BRIEF-Syros Announces 2018 Strategic Priorities And Expected Milestones

* SYROS ANNOUNCES 2018 STRATEGIC PRIORITIES AND EXPECTED MILESTONES

08 Jan 2018

BRIEF-Syros Announces Clinical Supply Agreement With Janssen To Evaluate SY-1425

* SYROS ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH JANSSEN TO EVALUATE SY-1425, ITS FIRST-IN-CLASS SELECTIVE RARΑ AGONIST, IN COMBINATION WITH DARATUMUMAB IN GENOMICALLY DEFINED AML AND MDS PATIENTS

02 Jan 2018

BRIEF-Syros Pharma Q3 loss per share $0.53

* Syros reports third quarter 2017 financial results and highlights accomplishments and upcoming milestones

08 Nov 2017

Earnings vs. Estimates